Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M175,765Revenue $M27,485Net Margin (%)51.7Altman Z-Score8.1
Enterprise Value $M177,242EPS $8.8Operating Margin %64.0Piotroski F-Score8
P/E(ttm)13.6Beneish M-Score-2.3Pre-tax Margin (%)62.4Higher ROA y-yY
Price/Book10.310-y EBITDA Growth Rate %--Quick Ratio2.4Cash flow > EarningsY
Price/Sales7.05-y EBITDA Growth Rate %27.2Current Ratio2.7Lower Leverage y-yN
Price/Free Cash Flow11.8y-y EBITDA Growth Rate %180ROA % (ttm)44.1Higher Current Ratio y-yY
Dividend Yield %0.4PEG0.5ROE % (ttm)93.9Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M1,470ROIC % (ttm)84.4Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDKen Fisher 2015-06-30 Add$97.72 - $122.21
($109.1)
$ 119.6010%Add 0.26%791,630
GILDJulian Robertson 2015-03-31 Reduce-5.61%$94.91 - $107.18
($101.54)
$ 119.6018%Reduce 56.64%231,511
GILDLeon Cooperman 2015-03-31 Sold Out -0.96%$94.91 - $107.18
($101.54)
$ 119.6018%Sold Out0
GILDFirst Eagle Investment 2015-03-31 Reduce-0.3%$94.91 - $107.18
($101.54)
$ 119.6018%Reduce 99.97%400
GILDNWQ Managers 2015-03-31 Buy 0.14%$94.91 - $107.18
($101.54)
$ 119.6018%New holding113,100
GILDJohn Rogers 2015-03-31 Add0.1%$94.91 - $107.18
($101.54)
$ 119.6018%Add 11.07%891,645
GILDJoel Greenblatt 2015-03-31 Add0.07%$94.91 - $107.18
($101.54)
$ 119.6018%Add 9.73%1,107,732
GILDDavid Dreman 2015-03-31 Buy 0.05%$94.91 - $107.18
($101.54)
$ 119.6018%New holding5,580
GILDKen Fisher 2015-03-31 Add$94.91 - $107.18
($101.54)
$ 119.6018%Add 2.35%789,615
GILDRonald Muhlenkamp 2015-03-31 Reduce$94.91 - $107.18
($101.54)
$ 119.6018%Reduce 0.09%218,740
GILDMario Gabelli 2015-03-31 Add$94.91 - $107.18
($101.54)
$ 119.6018%Add 16.13%49,470
GILDDodge & Cox 2015-03-31 Reduce$94.91 - $107.18
($101.54)
$ 119.6018%Reduce 5.76%4,250
GILDKen Heebner 2014-12-31 Sold Out -4.7%$89.45 - $114.22
($103.4)
$ 119.6016%Sold Out0
GILDJulian Robertson 2014-12-31 Add1.67%$89.45 - $114.22
($103.3)
$ 119.6016%Add 20.27%533,911
GILDLeon Cooperman 2014-12-31 Buy 0.96%$89.45 - $114.22
($103.54)
$ 119.6016%New holding612,500
GILDFirst Eagle Investment 2014-12-31 Add0.3%$89.45 - $114.22
($103.4)
$ 119.6016%Add 328672.00%1,315,088
GILDJoel Greenblatt 2014-12-31 Add0.26%$89.45 - $114.22
($103.3)
$ 119.6016%Add 51.98%1,009,462
GILDRonald Muhlenkamp 2014-12-31 Add0.24%$89.45 - $114.22
($103.4)
$ 119.6016%Add 6.10%218,945
GILDJohn Rogers 2014-12-31 Add0.17%$89.45 - $114.22
($103.4)
$ 119.6016%Add 24.68%802,803
GILDVanguard Health Care Fund 2014-12-31 Sold Out -0.1%$89.45 - $114.22
($103.4)
$ 119.6016%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MILLIGAN JOHN FPresident and COO 2015-07-07Sell100,000$114.444.51view
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2015-07-07Sell70,000$118.271.12view
Alton Gregg HEVP, Corp & Med Affairs 2015-07-01Sell17,000$116.732.46view
Carter Paul RutherfordEVP Commercial Ops 2015-07-01Sell3,000$118.241.15view
MARTIN JOHN CChairman and CEO 2015-07-01Sell150,000$116.462.7view
Cogan John FrancisDirector 2015-06-26Sell27,000$120.13-0.44view
Carter Paul RutherfordEVP Commercial Ops 2015-06-18Sell10,000$120-0.33view
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2015-06-15Sell70,000$117.671.64view
MILLIGAN JOHN FPresident and COO 2015-06-08Sell100,000$114.054.87view
MARTIN JOHN CChairman and CEO 2015-06-01Sell150,000$113.954.96view

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
Apple, Gilead and Hibbett Display Both Growth and Value Jul 29 2015 
shortlist Jul 19 2015 
shortlist Jul 19 2015 
shortlist Jul 19 2015 
shortlist Jul 19 2015 
shortlist Jul 19 2015 
It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
Weekly Insider Sells Highlight: GILD, AXTA, GME, DXCM Jul 14 2015 
Gilead Sciences is Still Undervalued Jul 06 2015 
Julian Robertson Discusses Greece Threat, Stocks and Apple Jun 30 2015 

More From Other Websites
4 Stocks Set to Crush Their 52-Week Highs Soon - Analyst Blog Aug 03 2015
10 S&P 500 companies with the fastest sales growth Aug 03 2015
Stock Market Today - 07/31/15 Jul 31 2015
Highway Bill to Spend $500 Million for Veterans’ Hepatitis Drugs Jul 31 2015
Q2 EPS Growth Falls To Mere 0.9%; Sales Fall 3.3% Jul 31 2015
This is Why Amgen is Soaring Jul 31 2015
These are the Biggest Risk to Biotech Jul 31 2015
8 Great Stocks for Investors Nearing Retirement Jul 31 2015
Merck's Ebola Vaccine Is 'Highly Effective' Jul 31 2015
1% Q2 Profit Growth Is S&P 500's Weakest Since '12 Jul 31 2015
No Rush to Hop on M&A Bandwagon, Says Gilead Sciences CFO Jul 30 2015
Dow falls on weak P&G results; Nasdaq up Jul 30 2015
Even With Recent Declines, Investors Still Love Biotech ETFs Jul 30 2015
Gilead Won't Run Out of Hep C Patients, or Dollars, Anytime Soon Jul 30 2015
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases Jul 30 2015
Gilead: the Apple of the Biotech World Jul 29 2015
Gilead hepatitis C drugs build road to Japan Jul 29 2015
U.S. stocks end higher as Fed leaves September hike on the table Jul 29 2015
Q2 Earnings Season Halftime Report Jul 29 2015
5 Big Stocks on Traders' Radars -- and What You Should Do With Them Now Jul 29 2015
Gilead beats Street 2Q forecasts on surge in sales, profit Jul 28 2015
Gilead Sciences Announces Third Quarter 2015 Dividend Jul 28 2015
Gilead Sciences Announces Second Quarter 2015 Financial Results Jul 28 2015
Gilead beats Street 2Q forecasts Jul 28 2015
Gilead Announces Executive Promotions Jul 27 2015
Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015 Jul 21 2015
Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens... Jul 21 2015
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily... Jul 03 2015
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily... Jul 03 2015
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen... Jul 01 2015
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen... Jul 01 2015
US stocks fall sharply on looming Greek debt default Jun 29 2015
Fund managers position for post-rate hike U.S. equity rally Jun 17 2015
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 9 Jun 08 2015
Zydelig® in Combination With Ofatumumab Improves Progression-Free Survival in Previously-Treated... May 31 2015
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of... May 28 2015
Gilead patents on costly hepatitis C drug challenged in five countries May 20 2015
Gilead patents on costly hepatitis C drug challenged in five countries May 20 2015
Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19 May 18 2015
S&P 500 closes at new record high May 14 2015
Speech given at the 113th Annual General Meeting of DMG MORI SEIKI AKTIENGESELLSCHAFT on 8 May 2015 May 08 2015
Gilead Sciences Acquires EpiTherapeutics May 06 2015
Mylan Launches Gilead Sciences' Sovaldi® Tablets in India May 04 2015
US STOCKS-Wall St rebounds as investors buy beaten-down shares May 01 2015
US STOCKS-Nasdaq snaps four-day losing streak as health stocks rebound May 01 2015
US STOCKS-Wall St opens higher as tech, health stocks rebound May 01 2015
US stocks up as Expedia surges while LinkedIn tanks May 01 2015
Gilead lifted by $3.6B 1Q sales of newest hepatitis C pill Apr 30 2015
Gilead Sciences Declares First Quarterly Cash Dividend Apr 30 2015
Gilead Sciences Announces First Quarter 2015 Financial Results Apr 30 2015
Gilead beats Street 1Q forecasts Apr 30 2015
Merck hurdles Wall Street forecasts Apr 28 2015
Aetna raises 2015 outlook after 1Q earnings tops forecasts Apr 28 2015
Merck tops Street 1Q forecasts Apr 28 2015
US stocks snap record-setting rally Apr 27 2015
Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C... Apr 25 2015
EU regulators warn against combining hep C drugs with amiodarone Apr 24 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK